Secondary lymphedema is a debilitating disease characterized by abnormal soft tissue swelling and caused by lymphatic system dysfunction. Despite a high prevalence of secondary lymphedema after cancer treatments, current management is supportive and there are no approved therapeutic agents that can thwart disease progression. We have previously demonstrated that 9-cis-retinoic acid (9-cisRA) has the potential to be repurposed for lymphedema as it mitigates disease by promoting lymphangiogenesis at the site of lymphatic injury. Although the efficacy of 9-cisRA has been demonstrated in previous studies, the mechanism of action is not completely understood. In this study, we demonstrate that when RXRα is specifically deleted in lymphatic endothelial cells, 9-cisRA fails to induce lymphangiogenesis in vitro and prevent pathologic progression of postsurgical lymphedema in vivo. These findings demonstrate that downstream nuclear receptor RXRα plays a critical role in the therapeutic efficacy of 9-cisRA in postsurgical lymphedema.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1096/fj.202200146RR | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The burden of lymphedema on quality of life.
Vasa
January 2025
Department of Orthopedic, Trauma and Plastic Surgery, University Hospital Leipzig, Germany.
Due to a lack of validated methodologies, this study aimed to evaluate the quality of life (QoL) among individuals affected by lymphedema and to compare them with the general population and common diseases. Patients were recruited from October 2023 till March 2024. The SF-36 and LYMQOL questionnaires were administered.
View Article and Find Full Text PDFUltrasound Examination of Skin, Fasciae and Subcutaneous Tissue: Optimizing Rehabilitation for Secondary Upper Limb Lymphedema.
Diagnostics (Basel)
December 2024
Department of Neurosciences, Institute of Human Anatomy, University of Padova, 35121 Padova, Italy.
Background: Lymphedema represents a frequent cause of disability for patients undergoing oncological treatments and, being a chronic, non-reversible pathology, requires targeted and continuous rehabilitation treatments. To date, the studies available on the use of ultrasound in patients with lymphedema mainly report descriptive data; therefore, with this study, we wanted to describe in a more objective way the typical ultrasound alterations found in these patients, measuring the thickness of the different superficial structures, and defining subcutis echogenicity.
Methods: 14 patients affected by secondary lymphedema of the upper limbs were enrolled in this cross-sectional observational study (12 had breast cancer and 2 with melanoma as their primary diagnosis).
Methodological description of knowledge translation: Implementation of clinical practice guidelines into clinical practice.
PM R
January 2025
Board Certified Clinical Specialist in Oncological Physical Therapy, Board Certified Clinical Specialist in Women's Health Physical Therapy, LANA Certified Lymphedema Therapist, Select Medical, ReVital Cancer Rehabilitation, Mechanicsburg, Pennsylvania, USA.
This methodological paper explores the intricacies of implementing evidence-based medicine in the health care sector specifically focusing on the clinical practice guideline (CPG) published by the American Physical Therapy Association's Academy of Oncologic Physical Therapy for diagnosing upper quadrant lymphedema secondary to cancer (diagnosis CPG). Although CPGs are widely available, their implementation into clinical practice remains inconsistent, slow, and complex. To address this challenge, this paper employs the Knowledge-to-Action framework, offering a detailed description of the seven stages through the lens of an in-progress case study on the implementation of the diagnosis CPG.
View Article and Find Full Text PDFComputed tomography scanning in the diagnosis of lower extremity phlebolymphedema.
J Vasc Surg Venous Lymphat Disord
January 2025
The RANE Center for Venous & Lymphatic Diseases, St. Dominic Hospital, Jackson, MS. Electronic address:
Objectives: Phlebolymphedema, the most common cause of secondary lymphedema in Western societies, seldom gets the attention it deserves. Diagnosis is often missed and when evaluated is through lymphoscintigraphy (LSG) which is cumbersome. This study aims to assess the role of computed tomography (CT) scanning in the diagnosis of phlebolymphedema of the lower extremities by comparing CT characteristics to the International Society of Lymphology (ISL) grading system and LSG.
View Article and Find Full Text PDFAnti-CTLA4 treatment reduces lymphedema risk potentially through a systemic expansion of the FOXP3 T population.
Nat Commun
December 2024
Division of Plastic Surgery, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Secondary lymphedema is a common sequel of oncologic surgery and presents a global health burden still lacking pharmacological treatment. The infiltration of the lymphedematous extremities with CD4T cells influences lymphedema onset and emerges as a promising therapy target. Here, we show that the modulation of CD4FOXP3CD25regulatory T (T) cells upon anti-CTLA4 treatment protects against lymphedema development in patients with melanoma and in a mouse lymphedema model.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!